The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial

Journal of Dermatology

Volumn 26, Issue 4, 1999, Pages 210-215

  Fleischer Jr , Alan B ^a,b   Feldman, Steven R ^a   Dekle, Catherine L ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Clinimetrics; Epidermiology; PASI; Skin diseases

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PSORIASIS; QUESTIONNAIRE; RATING SCALE; RISK ASSESSMENT; SCORING SYSTEM; SELF EVALUATION; SKIN DISEASE; VALIDATION PROCESS;

EID: 0345280000     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1999.tb03458.x     Document Type: Article

References (11)

1. Fredriksson T, Pettersson U: Severe psoriasis: oral therapy with a new retinoid, Dermatologica, 157: 238-244, 1978.
2. Harland CC, Whitaker RP, Barron JL, Holden CA: Increased urine neopterin levels in psoriasis, Br J Dermatol, 127: 453-457, 1992.
3. Laurahanta J, Geiger JM: A double-blind comparison of acitertin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis, Br J Dermatol, 121: 107-112, 1989.
4. Cecchi R, Seghieri G, Gironi A, Tuci F, Giomi A: Relationship between urinary albumin excretion and skin involvement in patients with psoriasis, Dermatology, 185: 93-95, 1992.
5. Collins P, Rogers S: Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis, Br J Dermatol, 127: 392-395, 1992.
6. Feldman SR, Fleischer AB, Reboussin DM, et al: The self-administered psoriasis area and severity index is valid and reliable, J Invest Dermatol, 106: 183-186, 1996.
7. Fleischer AB, Rapp SR, Reboussin DM, Vanarthos JC, Feldman SR: Patient measurement of psoriasis disease severity with a structured instrument, J Invest Dermatol, 102: 967-969, 1994.
8. Fleischer AB Jr, Feldman SR, Rapp SR, Reboussin DR, Exum ML, Clark AR: Alternative therapies are commonly used within a population of psoriasis patients, Cutis, 58: 216-220, 1996.
9. Feldman SR, Fleischer AB Jr, Rapp SR, Reboussin DM Bradham DD, Exum ML: The financial impact of psoriasis increases with psoriasis severity, J Am Acad Dermatol, 37: 564-569, 1997.
10. Lebwohl MG, Breneman DL, Goffe BS, et al: Tazarotene 0.1% gel plus coricosteroid cream in the treatment of plaque psoriasis, J Am Acad Dermatol, 39: 590-596, 1998.
11. Savolainen L, Kontinen J, Roning J, Oikarinen A: Application of machine vision to assess involved surface in patients with psoriasis, Br J Dermatol, 37: 359-400, 1997.